Clinical trial
Long Term Open Label Continuation Study
NCT00195650 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00195650 |
|---|---|
| Title | Long Term Open Label Continuation Study |
| Official title | A Multi-Center Continuation Study of the Human Anti-TNF Antibody D2E7 Administered as a Subcutaneous Injection in Patients With Rheumatoid Arthritis |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Biological |
| Interventions | Adalimumab |
| Enrollment | 846 |
| Start date | Jul 1, 2000 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | Sep 20, 2005 |
| Last update posted | Aug 31, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: